Vesilute Research Overview (also known as Bladder bioregulator, Urinary tract tetrapeptide bioregulator)
A tetrapeptide bioregulator developed by Khavinson's group targeting urothelial and smooth muscle gene expression in the bladder and lower urinary tract. Research interest includes age-related bladder dysfunction, overactive bladder, and urinary tract restoration.
What Is Vesilute?
Vesilute is a synthetic tetrapeptide bioregulator developed by Professor Vladimir Khavinson’s group at the St. Petersburg Institute of Bioregulation and Gerontology, designed to selectively modulate gene expression in the epithelial and smooth muscle cells of the bladder and lower urinary tract. It belongs to the same family of short peptide bioregulators as Vesugen (blood vessels), Testagen (testes), and Prostamax (prostate gland).
The Khavinson framework posits that organ-derived tetrapeptides carry sequence complementarity to interact with tissue-specific DNA regulatory elements, effectively signaling aging cells to restore more youthful patterns of gene transcription. Vesilute targets the urothelium (bladder lining epithelium) and the detrusor smooth muscle, with proposed research applications in age-related bladder dysfunction, urinary incontinence, and bladder tissue restoration following infection or inflammation.
Vesilute is not approved as a therapeutic agent in the United States or European Union and is available for research use only (RUO).
Mechanism of Action
Vesilute is proposed to act through sequence-specific DNA binding in urothelial and smooth muscle cells of the bladder wall. Khavinson’s laboratory model identifies short peptide bioregulators as molecules capable of minor-groove DNA interaction at complementary nucleotide sequences, altering histone acetylation states and recruiting transcription factors governing proliferation, differentiation, and inflammatory modulation in target tissue.
In the context of bladder biology, the relevant downstream targets include: (1) genes governing urothelial barrier integrity (uroplakins, claudins), which deteriorate with age and recurrent infection; (2) detrusor smooth muscle contractility regulatory genes, which when dysregulated produce overactive bladder (OAB) or underactive bladder phenotypes; and (3) inflammatory mediators including IL-6, TNF-α, and prostaglandin E2, elevated in chronic cystitis and urinary tract aging.
As with other Khavinson bioregulators, Vesilute is not proposed to produce acute pharmacological effects but rather to progressively restore transcriptional profiles toward younger, more functional states over repeated treatment courses.
Quick Reference
| Literature-Reported Dose Range | 1–2 mg per injection |
| Literature-Reported Frequency | Once daily |
| Sites Reported in Studies | SubQ: abdomen, thigh, or upper arm |
| Timing | AM or PM, consistent daily timing |
| Literature-Reported Cycle Length | 20–30 days per course |
| Literature-Reported Washout | 2–3 courses per year; minimum 2 months off, 2–3× per year |
| Storage | Lyophilized: 2–8°C; Reconstituted: use within 30 days at 2–8°C; protect from light |
Research Indications
Bladder & Urological Research
Overactive Bladder Research
Khavinson institutional data report reductions in urgency episode frequency and improvement in bladder capacity over multi-course Vesilute protocols in elderly subjects.
Stress Urinary Incontinence
Detrusor and pelvic floor regulatory gene expression changes observed in animal models; human data limited to case series from Russian institutional practice.
Age-Related Bladder Decline
Positioned as a geroprotective agent for the lower urinary tract; normalized urothelial proliferation indices in aging rodent models across Khavinson studies.
Urothelial Research
Post-Infection Bladder Restoration
Case data from Russian clinical contexts report accelerated resolution of post-cystitis mucosal changes and faster return of normal bladder capacity following acute UTI.
Urothelial Barrier Studies
Limited preclinical data suggest potential urothelial protective effects and barrier integrity support in radiation and inflammatory exposure models.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
| Research Application | Dose | Frequency | Route |
|---|
| Standard Protocol | 1–2 mg | Once daily | SubQ |
| Bladder Restoration Course | 1 mg | Once daily | SubQ |
Peptide Interactions
Both are lower urogenital bioregulators (Prostamax: prostate; Vesilute: bladder). Stacking targets complementary pelvic floor tissue types in aging male research models.
BPC-157 promotes mucosal healing and angiogenesis; may support bladder urothelial repair in post-infection or post-inflammatory research protocols.
KPV carries mucosal anti-inflammatory activity via MC1R; may complement Vesilute’s tissue-regulatory effects in inflammatory bladder research contexts.
Immune bioregulator may synergize with Vesilute in post-infection recovery by supporting immune reconstitution alongside bladder tissue restoration.
Reported Research Timeline
01Course 1 (Days 1–20): Regulatory signaling in urothelial and detrusor cells initiated; minimal acute symptomatic effects expected within first cycle.
02Course 2–3 (Month 3–6): Reduction in urgency episode frequency and improved subjective bladder capacity reported in elderly subjects across multiple courses.
03Course 4+ (Month 6–12+): Cumulative geroprotective benefit across lower urinary tract tissue; longitudinal evaluation across 1–2 years recommended for full assessment.
Side effects (reported in cited studies): usually minimal; no serious adverse effects in available preclinical and early human data
Most common (reported in cited studies): mild injection-site erythema; transient soreness at SubQ site
Safety Notes
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
Generally well-tolerated in available preclinical and early human data. No serious adverse effects published in Khavinson institutional research.
Not a substitute for urological evaluation. Urinary symptoms (urgency, frequency, incontinence, hematuria) require proper medical evaluation. Vesilute has no antimicrobial properties.
No interaction data available with anticholinergic agents (e.g., oxybutynin, solifenacin) used for overactive bladder. Caution warranted when combining with pharmacological urological treatments.
Injection-site reactions (mild erythema, transient soreness) possible. Rotate SubQ sites.
Storage: Lyophilized at 2–8°C; reconstituted stable up to 30 days at 2–8°C; protect from light.
RUO only. Procure from vendors with third-party CoA, HPLC purity ≥98%, and sterility documentation.
Seek Medical Attention If:
Urinary symptoms that worsen rather than improve during a course
Persistent injection site reactions (redness, pain, or swelling beyond 48 hours)
Signs of allergic reaction (hives, difficulty breathing, or facial swelling)
Always consult a licensed physician before and during use
Quality Indicators
Verified Marker
Lyophilized Powder Appearance
White to off-white lyophilized powder. Discard any vial with visible discoloration or moisture intrusion.
Verified Marker
Certificate of Analysis (CoA)
Third-party HPLC purity ≥98%; mass spectrometry confirmation of tetrapeptide sequence; LAL endotoxin ≤2 EU/mg.
Verified Marker
Sterility Testing
USP-compliant sterility results from vendor for injectable-grade vials.
Expected
Reconstituted Solution Clarity
Clear, colorless solution after reconstitution. Turbidity or particulates indicate degradation.
Expected
Packaging Integrity
Intact crimp cap and rubber stopper on lyophilized vial.
Red Flag
Pre-mixed liquid formulations
Vesilute should be supplied as lyophilized powder requiring reconstitution. Pre-filled syringes or liquid vials indicate inadequate quality control.
Research Citations
- Peptides of pineal gland and thymus prolong human life
Khavinson VKh, Morozov VG. Neuroendocrinology Letters. 2003;24(3–4):233–240. - Gerontological Aspects of Genome Peptide Regulation
Khavinson VKh, Malinin VV. Karger: Basel, 2005. - Peptide regulation of gene expression and functional activity of urothelial cells
Khavinson VKh, Linkova NS, Kozhevnikova E, et al. Bulletin of Experimental Biology and Medicine. 2010. - Peptide bioregulators and aging
Khavinson VKh, Anisimov VN. Biogerontology. 2008;9(2):135–142.
Research Focus
Bladder health, Overactive bladder, Urinary aging, Urothelial restoration, Khavinson bioregulator
Frequently Asked Questions
What should researchers watch for with Vesilute?
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
What should researchers expect over time with Vesilute?
Course 1 (Days 1–20): Regulatory signaling in urothelial and detrusor cells initiated; minimal acute symptomatic effects expected within first cycle.
How is Vesilute typically administered in research?
As reported in cited literature and research-community logs (see Research Citations below) — not a personal dosing recommendation.
Browse all peptides in the Encyclopedia →